Protara Therapeutics (NASDAQ:TARA) PT Lowered to $25.00 at Oppenheimer

Protara Therapeutics (NASDAQ:TARA) had its price objective decreased by Oppenheimer from $30.00 to $25.00 in a research report released on Monday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, HC Wainwright restated a buy rating and set a $23.00 price objective on shares of Protara Therapeutics in a report on Thursday, August 8th.

Protara Therapeutics Trading Up 3.5 %

Protara Therapeutics stock opened at $2.05 on Monday. The stock has a fifty day moving average price of $2.24 and a 200 day moving average price of $2.97. Protara Therapeutics has a 52 week low of $1.04 and a 52 week high of $5.24. The firm has a market capitalization of $42.29 million, a P/E ratio of -0.55 and a beta of 1.85.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.37. As a group, equities analysts predict that Protara Therapeutics will post -3.02 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Opaleye Management Inc. sold 11,396 shares of Protara Therapeutics stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $2.44, for a total transaction of $27,806.24. Following the transaction, the insider now owns 56,500 shares in the company, valued at approximately $137,860. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 177,703 shares of company stock valued at $441,470. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Protara Therapeutics

A number of large investors have recently modified their holdings of TARA. Oppenheimer & Co. Inc. purchased a new position in Protara Therapeutics in the 1st quarter worth approximately $40,000. Marshall Wace LLP acquired a new position in shares of Protara Therapeutics during the second quarter worth $161,000. Renaissance Technologies LLC boosted its stake in shares of Protara Therapeutics by 77.8% in the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock valued at $313,000 after purchasing an additional 65,800 shares during the period. CVI Holdings LLC acquired a new stake in Protara Therapeutics during the 2nd quarter valued at $630,000. Finally, Ikarian Capital LLC increased its stake in Protara Therapeutics by 7.4% during the 1st quarter. Ikarian Capital LLC now owns 202,701 shares of the company’s stock worth $813,000 after buying an additional 14,037 shares during the period. Institutional investors and hedge funds own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.